Cited by 311SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

MERS-CoV spike protein: a key target for antivirals

Open access

Du, Lanying, Yang, Yang, Zhou, Yusen, Lu, Lu, Li, Fang, Jiang, Shibo·2017·Expert Opinion on Therapeutic Targets

DOI 10.1080/14728222.2017.1271415PMC PMC5457961

Open this paper in CoChat — free account

Abstract

INTRODUCTION: The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/14728222.2017.1271415

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, M. J. S., Lai, S., Poon, L. L. M., Guan, Y., Yam, L., Lim, W., Nicholls, J. M., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,916
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,035
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003
Zhong, N., Zheng, B., Li, Y., Poon, L., Xie, Z., Chan, K., Li, P. H., Tan, S., Chang, Q., Xie, J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14630-2 · Cited by 1,578
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Middle East respiratory syndrome
Zumla, A. I., Hui, D. S. C., & Perlman, S. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,306
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,185

Show all 98 references

Research works printed but not linked: 1

Van BS, 2012, MBio, 3

Sorted by citations

Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Self-citation
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
Self-citation
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 963
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tang, T., Bidon, M. K., Jaimes, J. A., Whittaker, G. R., & Daniel, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104792 · Cited by 767
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)
Shanmugaraj, B., Siriwattananon, K., Wangkanont, K., & Phoolcharoen, W. (2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0773 · Cited by 492
Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 434
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 387
CoV-AbDab: the coronavirus antibody database
Raybould, M. I. J., Kovaltsuk, A., Marks, C., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa739 · Cited by 383
A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2
Atzrodt, C. L., Maknojia, I. H., McCarthy, R. D. P., Oldfield, T. M., Po, J., Ta, K. T. L., Stepp, H. E., & Clements, T. P. (2020) · FEBS Journal · doi:10.1111/febs.15375 · Cited by 362
An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies
Jiang, S., Du, L., & Shi, Z. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1723441 · Cited by 330
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
Łoczechin, A., Séron, K., Barras, A., Giovanelli, E., Belouzard, S., Chen, Y., Metzler‐Nolte, N., Boukherroub, R., Dubuisson, J., & Szunerits, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b15032 · Cited by 320
A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin
Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1754293 · Cited by 293
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
Li, K., Huang, B., Wu, M., Zhong, A., Li, L., Cai, Y., Wang, Z., Wu, L., Zhu, M., Li, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19943-y · Cited by 257
CORONAVIRUS DISEASE 2019 (COVID-19): A LITERATURE REVIEW
Ibrahım, B., & Önem, E. (2021) · Gevher Nesibe Journal IESDR · doi:10.46648/gnj.200 · Cited by 251
Membrane Binding Proteins of Coronaviruses
Alsaadi, E. A. J., & Jones, I. M. (2019) · Future Virology · doi:10.2217/fvl-2018-0144 · Cited by 231
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224
SARS-CoV-2 Infectivity and Neurological Targets in the Brain
Lukiw, W. J., Pogue, A. I., & Hill, J. M. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00947-7 · Cited by 226
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 230
Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning
Kadioglu, O., Saeed, M. E. M., Greten, H. J., & Efferth, T. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104359 · Cited by 191
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin- Converting Enzyme 2 as a Potential Drug Target - A Perspective
Magrone, T., Magrone, M., & Jirillo, E. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200427112902 · Cited by 186
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Tree, J. A., Wallace, A., Amcheslavsky, A., Yılmaz, N. K., Buttigieg, K. R., Elmore, M. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18058-8 · Cited by 185
Antibodies and Vaccines Target RBD of SARS-CoV-2
Min, L., & Sun, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.671633 · Cited by 159
Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines
Chen, X., Han, W., Wang, G., & Zhao, X. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.106 · Cited by 158
Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses
Nasrollahzadeh, M., Sajjadi, M., Soufi, G. J., Iravani, S., & Varma, R. S. (2020) · Nanomaterials · doi:10.3390/nano10061072 · Cited by 161
COVID-19: Progress in diagnostics, therapy and vaccination
Liu, X., Liu, C., Liu, G., Luo, W., & Xia, N. (2020) · Theranostics · doi:10.7150/thno.47987 · Cited by 159
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 155
A Comprehensive Review About SARS-CoV-2
Haque, S. M., Ashwaq, O., Sarief, A., & Azad John Mohamed, A. K. (2020) · Future Virology · doi:10.2217/fvl-2020-0124 · Cited by 121
Prospects for a MERS-CoV spike vaccine
Zhou, Y., Jiang, S., & Du, L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506702 · Cited by 126
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
Zhou, Y., Yang, Y., Huang, J., Jiang, S., & Du, L. (2019) · Viruses · doi:10.3390/v11010060 · Cited by 120
Analysis of COVID‐19 vaccines: Types, thoughts, and application
Han, X., Xu, P., & Ye, Q. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23937 · Cited by 119
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
Widjaja, I., Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., van Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado, R., Grosveld, F., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1597644 · Cited by 115
Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach
Ahammad, I., & Lira, S. S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.213 · Cited by 112
Nanobiosensors as new diagnostic tools for SARS, MERS and COVID-19: from past to perspectives
Antiochia, R. (2020) · Microchimica Acta · doi:10.1007/s00604-020-04615-x · Cited by 109
Designing a multi-epitope vaccine candidate to combat MERS-CoV by employing an immunoinformatics approach
Mahmud, S., Rafi, M. O., Paul, G. K., Promi, M. M., Shimu, M. S. S., Biswas, S., Emran, T. B., Dhama, K., Alyami, S. A., Moni, M. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92176-1 · Cited by 104
A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
Zhao, G., He, L., Sun, S., Qiu, H., Tai, W., Chen, J., Li, J., Chen, Y., Guo, Y., Wang, Y., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00837-18 · Cited by 103
SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen
Wang, Y., Wang, L., Cao, H., & Liu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26320 · Cited by 94
Emerging Microbes & Infections
Yuen, K. (2016) · Cited by 92
Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD
Bouback, T. A., Pokhrel, S., Albeshri, A. O., Aljohani, A. M., Samad, A., Alam, R., Hossen, M. S., AlGhamdi, K. M., Talukder, M. E. K., Ahammad, F., et al. (2021) · Molecules · doi:10.3390/molecules26164961 · Cited by 85
A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection
Remali, J., & Aizat, W. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.589044 · Cited by 80
An Overview of Vaccine Development for COVID-19
Shahcheraghi, S. H., Ayatollahi, J., Aljabali, A. A. A., Shastri, M. D., Shukla, S. D., Chellappan, D. K., Jha, N. K., Anand, K., Katari, N. K., Mehta, M., et al. (2021) · Therapeutic Delivery · doi:10.4155/tde-2020-0129 · Cited by 79
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection
Geng, Q., Tai, W., Baxter, V. K., Shi, J., Wan, Y., Zhang, X., Montgomery, S. A., Taft-Benz, S., Anderson, E. J., Knight, A. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009897 · Cited by 78
Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses
Chen, Z., Boon, S. S., Wang, M. H., Chan, R. W. Y., & Chan, P. K. S. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2020.114032 · Cited by 76
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Khan, A., Khan, T., Ali, S., Aftab, S., Wang, Y., Wang, Q., Khan, M., Suleman, M., Ali, S., Heng, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112176 · Cited by 75
Structural mapping of antibody landscapes to human betacoronavirus spike proteins
Bangaru, S., Antanasijevic, A., Kose, N., Sewall, L. M., Jackson, A. M., Suryadevara, N., Zhan, X., Torres, J. L., Copps, J., de la Peña, A. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn2911 · Cited by 65
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
Nyon, M. P., Du, L., Tseng, C.-T. K., Seid, C. A., Pollet, J. B. K., Naceanceno, K. S., Agrawal, A. S., Algaissi, A. A., Peng, B., Tai, W., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.065 · Cited by 68
The perspectives of biomarker-based electrochemical immunosensors, artificial intelligence and the Internet of Medical Things toward COVID-19 diagnosis and management
Yadav, A. K., Verma, D., Kumar, A., Kumar, P., & Solanki, P. R. (2021) · Materials Today Chemistry · doi:10.1016/j.mtchem.2021.100443 · Cited by 65
Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus
Kim, M. H., Kim, H. J., & Chang, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220196 · Cited by 63
Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells
Kato, T., Takami, Y., Deo, V. K., & Park, E. Y. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.10.007 · Cited by 62
Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to
Ojha, P. K., Kar, S., Jillella, G. K., Roy, K., & Leszczyński, J. (2020) · Molecular Diversity · doi:10.1007/s11030-020-10134-x · Cited by 59
SARS-CoV-2: vaccines in the pandemic era
Li, D., & Li, Q. (2021) · Military Medical Research · doi:10.1186/s40779-020-00296-y · Cited by 61
Current development of COVID-19 diagnostics, vaccines and therapeutics
Zhang, N., Li, C., Hu, Y., Li, K., Liang, J., Wang, L., Du, L., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.05.001 · Cited by 55
A Review of Human Coronaviruses’ Receptors: The Host-Cell Targets for the Crown Bearing Viruses
Nassar, A. M., Ibrahim, I. M., Amin, F. G., Magdy, M., Elgharib, A. M., Azzam, E. B., Nasser, F., Yousry, K., Shamkh, I. M., Mahdy, S. M., et al. (2021) · Molecules · doi:10.3390/molecules26216455 · Cited by 59
A Comparative Analysis of Factors Influencing Two Outbreaks of Middle Eastern Respiratory Syndrome (MERS) in Saudi Arabia and South Korea
Willman, M., Kobasa, D., & Kindrachuk, J. (2019) · Viruses · doi:10.3390/v11121119 · Cited by 56
Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
Khatri, I., Staal, F. J. T., & van Dongen, J. J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570018 · Cited by 54
Development of Small-Molecule MERS-CoV Inhibitors
Liang, R., Wang, L., Zhang, N., Deng, X., Su, M., Su, Y., Hu, L., He, C., Ying, T., Jiang, S., et al. (2018) · Viruses · doi:10.3390/v10120721 · Cited by 53
From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
Ma, C., Su, S., Wang, J., Wei, L., Du, L., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.05.004 · Cited by 51
The free fatty acid–binding pocket is a conserved hallmark in pathogenic β-coronavirus spike proteins from SARS-CoV to Omicron
Toelzer, C., Gupta, K., Yadav, S. K. N., Hodgson, L. R., Williamson, M. K., Buzas, D., Borucu, U., Powers, K. T., Stenner, R., Vasileiou, K., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9179 · Cited by 49
Why Have Nanotechnologies Been Underutilized in The Global Uprising Against The Coronavirus Pandemic?
Uskoković, V. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0163 · Cited by 52
Structural Basis of SARS-CoV-2– and SARS-CoV–Receptor Binding and Small-Molecule Blockers as Potential Therapeutics
Sivaraman, H., Er, S. Y., Choong, Y. K., Gavor, E., & Sivaraman, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061220-093932 · Cited by 49
Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic
Yu, M., Zhang, T., Zhang, W., Sun, Q., Li, H., & Li, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.628551 · Cited by 52
Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus
Deng, Y. L., Lan, J., Bao, L., Huang, B., Ye, F., Chen, Y., Yao, Y., Wang, W., Qin, C., & Tan, W. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0056-7 · Cited by 50
Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2
Shahrajabian, M. H., Sun, W., & Cheng, Q. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1797369 · Cited by 50
Thermodynamic equilibrium dose-response models for MERS-CoV infection reveal a potential protective role of human lung mucus but not for SARS-CoV-2
Gale, P. (2020) · Microbial Risk Analysis · doi:10.1016/j.mran.2020.100140 · Cited by 49
COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
Filardi, T., & Morano, S. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01318-1 · Cited by 48
Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment
Witika, B. A., Makoni, P. A., Mweetwa, L. L., Ntemi, P. V., Chikukwa, M. T. R., Matafwali, S. K., Mwila, C., Mudenda, S., Katandula, J., & Walker, R. B. (2020) · Molecules · doi:10.3390/molecules25245952 · Cited by 49
Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor
Suleman, M., Yousafi, Q., Ali, J., Ali, S. S., Hussain, Z., Ali, S., Waseem, M., Iqbal, A., Ahmad, S., Khan, A., et al. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104936 · Cited by 49
Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection
Jia, W., Channappanavar, R., Zhang, C., Li, M., Zhou, H., Zhang, S., Zhou, P.-P., Xu, J., Shan, S., Shi, X., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1620083 · Cited by 45
Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection
Habib, A. M. G., Khalifa, M., Zouaoui, B. R., Taha, M. A. H., Mohammed, B. S., & Saquib, N. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4555-5 · Cited by 45
Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
Wang, X., Xia, S., Wang, Q., Xu, W., Li, W., Lu, L., & Jiang, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113843 · Cited by 46
The Inclusive Review on SARS-CoV-2 Biology, Epidemiology, Diagnosis, and Potential Management Options
Parikhani, A. B., Bazaz, M., Bamehr, H., Fereshteh, S., Amiri, S., Salehi-Vaziri, ‪., Arashkia, A., & Azadmanesh, K. (2021) · Current Microbiology · doi:10.1007/s00284-021-02396-x · Cited by 47
A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
Rabaan, A. A., Al-Ahmed, S. H., Bazzi, A. M., & Alhani, H. M. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000565 · Cited by 44
Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial
Mousavi, S. M., Hashemi, S. A., Parvin, N., Gholami, A., Ramakrishna, S., Omidifar, N., Moghadami, M., Chiang, W., & Mazraedoost, S. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1845201 · Cited by 42
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection
Marchi, S., Viviani, S., Remarque, E. J., Ruello, A., Bombardieri, E., Bollati, V., Milani, G. P., Manenti, A., Lapini, G., Rebuffat, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253977 · Cited by 43
Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
He, L., Tai, W., Li, J., Chen, Y., Gao, Y., Li, J., Sun, S., Zhou, Y., Du, L., & Zhao, G. (2019) · Viruses · doi:10.3390/v11020166 · Cited by 43
Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike
Trigueiro-Louro, J. M., Correia, V., Figueiredo-Nunes, I., Gíria, M., & Rebelo‐de‐Andrade, H. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.07.017 · Cited by 44
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Du, L., Yang, Y., Zhang, X., & Li, F. (2021) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 43
A Fusion Peptide in the Spike Protein of MERS Coronavirus
Alsaadi, E. A. J., Neuman, B. W., & Jones, I. M. (2019) · Viruses · doi:10.3390/v11090825 · Cited by 39
SARS-CoV-2 Vaccine Development: An Overview and Perspectives
Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40
MERS Coronavirus: An Emerging Zoonotic Virus
Li, F., & Du, L. (2019) · Viruses · doi:10.3390/v11070663 · Cited by 38
The variants of SARS‐CoV‐2 and the challenges of vaccines
Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 37
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
Sheikhshahrokh, A., Ranjbar, R., Saeidi, E., Dehkordi, F. S., Heiat, M., Ghasemi-Dehkordi, P., & Goodarzi, H. (2020) · Iranian Journal of Public Health · doi:10.18502/ijph.v49is1.3666 · Cited by 36
Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
Mokhtary, P., Pourhashem, Z., Mehrizi, A. A., Sala, C., & Rappuoli, R. (2022) · Biomedicines · doi:10.3390/biomedicines10081861 · Cited by 44
Nanomaterials-Based Sensors for Respiratory Viral Detection: A Review
Naikoo, G. A., Awan, T., Hassan, I. U., Salim, H., Arshad, F., Ahmed, W., Asiri, A. M., & Qurashi, A. (2021) · IEEE Sensors Journal · doi:10.1109/jsen.2021.3085084 · Cited by 36
Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models
Wang, Y., Sun, J., Zhu, A., Zhao, J., & Zhao, J. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.80 · Cited by 36
Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design
Tiwari, M., & Mishra, D. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104441 · Cited by 36
Brief on Recent Application of Liposomal Vaccines for Lower Respiratory Tract Viral Infections: From Influenza to COVID-19 Vaccines
Attia, M., Essa, E. A., Elebyary, T. T., Faheem, A., & Elkordy, A. (2021) · Pharmaceuticals · doi:10.3390/ph14111173 · Cited by 36
An Outbreak of a New Infectious Disease COVID-19: β-coronaviruses as a Threat to Global Healthcare
Витальевич, Г. Д., Khantimirova, L. M., Шевцов, В. А., Рукавишников, А. В., Меркулов, В. А., & Olefir, Y. V. (2020) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2020-20-1-6-20 · Cited by 32
The Spike of SARS-CoV-2: Uniqueness and Applications
Kumavath, R., Barh, D., Andrade, B. S., Imchen, M., Aburjaile, F. F., Ch, A., Rodrigues, D. L. N., Tiwari, S., Alzahrani, K. J., Goés‐Neto, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663912 · Cited by 34
Advances in mRNA and other vaccines against MERS-CoV
Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 36
SARS-Cov-2 Spike-S1 Antigen Test Strip with High Sensitivity Endowed by High-Affinity Antibodies and Brightly Fluorescent QDs/Silica Nanospheres
Tao, S., Zhao, X., Bao, D., Liu, X., Zhang, W., Zhao, L., Tang, Y., Wu, H., Ye, H., Yang, Y., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c03434 · Cited by 32
Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection
Liu, X.-H., Zhang, X., Lü, Z., Zhu, Y., & Wang, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111035 · Cited by 30
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 38
Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice
Li, E., Yan, F., Huang, P., Chi, H., Xu, S., Li, G., Liu, C., Feng, N., Wang, H., Zhao, Y., et al. (2020) · Viruses · doi:10.3390/v12010125 · Cited by 30
Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
Lan, Q., Wang, L., Jiao, F., Lu, L., Xia, S., & Jiang, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28143 · Cited by 30
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Bhatta, A., Sahoo, S., Teja, K. B., & Tomar, S. J. (2023) · Springer eBooks · doi:10.1007/978-981-99-2820-0_6 · Cited by 31

Authors: Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S.
Affiliations: New York Blood Center (US)
University of Minnesota (US)
Beijing Institute of Microbiology and Epidemiology (CN)
Shanghai Medical College of Fudan University (CN)
Corresponding author: Du, Lanying
Jiang, Shibo
ORCID: Du, Lanying
Yang, Yang
Zhou, Yusen
Lu, Lu
Li, Fang
Jiang, Shibo
Venue: Expert Opinion on Therapeutic Targets
Publisher: Informa UK Limited
Published: 2016-12-21
Volume: 21
Issue: 2
Pages: 131-143
ISSN: 1472-8222 (ISSN-L)
1744-7631
DOI: 10.1080/14728222.2017.1271415
PMC: PMC5457961
OpenAlex: W2560886679
Cited by: 301
References: 98
Citations by year: 2026: 10 · 2025: 6 · 2024: 30 · 2023: 25 · 2022: 28 · 2021: 75 · 2020: 87 · 2019: 27 · 2018: 10 · 2017: 2 · 2016: 1
FWCI: 2.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Expert Opinion on Therapeutic Targets (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (R01AI089728, R01AI098775, R01AI110700, R21AI109094)
New York Blood Center (NYB000348)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: MERS-CoV, spike protein, dipeptidyl peptidase IV, receptor binding domain, heptad repeat 1, neutralizing monoclonal antibodies, antiviral peptides, viral entry inhibition, membrane fusion inhibition, antibody combination therapy, peptide optimization
MeSH terms: Animals, Antibodies, Monoclonal, Antiviral Agents, Humans, Peptides, Drug Design, Coronavirus Infections, Virus Internalization, Antibodies, Neutralizing, Middle East Respiratory Syndrome Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MERS-CoV spike protein: a key target for antivirals

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks